IPO
The company is banking on investors approving of its approach to harness exosomes, which had once been considered the cells’ garbage cans, as a means of pioneering a new class of biologic medicines.
Parnell Pharmaceuticals Holdings Ltd, a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Friday, 31 May 2019 at 9:00 a.m.
Polarean Imaging announces that the total number of shares in issue and total voting rights as at the date of this announcement is 101,435,933 ordinary shares of £0.00037 each.
Karolinska Development AB has published its Annual Report for 2018.
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Monday, May 6, 2019 at 5pm ET to discuss first quarter 2019 financial results and provide a corporate update.
Auris Medical Holding Ltd. announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20.
Recipharm AB will publish its interim report for January-March 2019 on 3 May at 07:45 am CET.
Biom’up announced its full-year results for the year ending December 31, 2018, as approved by the Company’s Board of Directors on April 29, 2019, and provided an update on its operations.
Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled €314.1 million as of March 31, 2019
Fusion Antibodies plc announces that Dr Paul Kerr, Chief Executive Officer of the Company, has purchased 1,290 ordinary shares in the Company at a price of 77 pence per Ordinary Share.
PRESS RELEASES